More

    Europe Markets

    Fluenz | European Medicines Agency (EMA)

    OverviewFluenz is a vaccine used to help protect children and adolescents from 2 years to less than 18 years old against seasonal influenza...

    Omlyclo | European Medicines Agency (EMA)

    OverviewOmlyclo is a medicine used to improve the control of severe persistent asthma caused by an allergy. It is used as an add-on...

    Advagraf | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP)...

    mResvia | European Medicines Agency (EMA)

    OverviewmResvia is a vaccine for protecting against lower respiratory tract disease (diseases of the lungs such as bronchitis or pneumonia) caused by respiratory...

    Xalkori | European Medicines Agency (EMA)

    OverviewXalkori is a cancer medicine used on its own to treat adults with a type of lung cancer called non-small cell lung cancer...

    Fampridine Accord | European Medicines Agency (EMA)

    OverviewFampridine Accord is a medicine used to improve walking ability in adults with multiple sclerosis (MS) who have a walking disability.MS is a...

    Steqeyma | European Medicines Agency (EMA)

    OverviewSteqeyma is a medicine used to treat: • moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin). It is...

    Wezenla | European Medicines Agency (EMA)

    OverviewWezenla is a medicine used to treat:moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin). It is used in adults and children above the age of 6 years whose condition has not improved with, or who cannot use, other systemic...

    Eklira Genuair | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Eklira Genuair. It explains how the Agency assessed the medicine to...

    Bretaris Genuair | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Bretaris Genuair. It explains how the Agency assessed the medicine to...

    Eptifibatide Accord | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Eptifibatide Accord. It explains how the Agency assessed the medicine to...

    Brimica Genuair | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Brimica Genuair. It explains how the Agency assessed the medicine to...

    Avastin | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Avastin. It explains how the Agency assessed the medicine to recommend...

    Relvar Ellipta | European Medicines Agency (EMA)

    OverviewRelvar Ellipta is an inhaler for treating asthma and chronic obstructive pulmonary disease (COPD).In asthma, it is used for regular treatment of patients...

    Revinty Ellipta | European Medicines Agency (EMA)

    OverviewRevinty Ellipta is an inhaler for treating asthma and chronic obstructive pulmonary disease (COPD). In asthma, it is used for regular treatment of...

    Lyrica | European Medicines Agency (EMA)

    OverviewThis is a summary of the European public assessment report (EPAR) for Lyrica. It explains how the Committee for Medicinal Products for Human...